Converging GLP-1 / tirzepatide / semaglutide / retatrutide postmarket safety

FDA continues warnings on compounded vs brand; overdoses rising (95 cases/month, 265% increase). Gallup poll shows 15% of Americans have tried, 11% currently using, 19% use compounded versions. FDA scientists warn against expanded peptide access as RFK Jr. reshapes advisory panel with industry-tied members. FDA names peptide compounding committee. Ongoing: muscle loss, bone density, oral side effects, liver benefits, retatrutide phase 3, black market risks, telehealth enforcement. New: Patient safety guides for compounded GLP-1s (Q&A, red flags/green lights) being published. New: Compounded semaglutide safety PDF summarizing FDA warnings. New: Microdosing GLP-1s trending – Forbes article warns against unapproved dosing practices. New: Article warns GLP-1s may be 'disaster in the making' – clinician cautions about muscle loss and nutritional depletion. New: Practical guide on reading compounding pharmacy labels for GLP-1s. New: JAMA study on online GLP-1 prescribing finds 45 of 49 sites prescribed in as little as 5 minutes with minimal verification, and a self-silencing phenomenon where patients downplay side effects to keep prescriptions. New: BMJ fact-check on retatrutide black market death clarifies death from unregulated sources. New: TGA safety alert on GLP-1 medicines and rare, severe vision loss (NAION). New: FDA Pharmacy Compounding Advisory Committee meeting (July 23-24, 2026) discusses compounded peptides. New: 'Ozempic tongue' side effect (metallic taste, burning, dry mouth) gaining attention. New: Cambridge professor warns GLP-1s may cause 'unexpected babies' by interfering with absorption of oral contraceptives and HRT – a new, concrete side effect with major public health implications. New: BMJ study finds 37-68% higher alopecia risk with GLP-1s vs other diabetes drugs – hair loss as overlooked side effect. New: RFK Jr.-stacked FDA advisory panel approves peptides over scientists' objections – six of eight appointees sell peptides, raising conflict-of-interest concerns. New: NABP building national adverse-event clearinghouse for compounded drugs – addresses reporting gap, signals regulatory response. New: Yo-yo dieting study (1,400 people) reinforces muscle loss concern with GLP-1s – supports need for resistance training and protein during weight loss. New: 'Temporal wasting' side effect gaining attention – cosmetic concern, adds to known side effect profile. New: 'Ozempic hair' article explains telogen effluvium from rapid weight loss, not direct drug effect, with prevention tips – adds practical patient education context alongside BMJ alopecia study. New: Poison center calls skyrocket to 23,000 nationally, Illinois doubling in one year – reinforces need for regulated sourcing and patient education. Latest: PCAC voted to recommend six peptides for compounding despite FDA scientists' safety concerns – reinforces regulatory shift under RFK Jr. influence. New: Observational study suggests GLP-1s may protect against AMD (age-related macular degeneration) – a positive counterpoint to NAION risk, but causation unclear.